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Differential Requirement for CD80 and CD80/CD86-Dependent
Costimulation in the Lung Immune Response to an Influenza
Virus Infection1
Joanne M. Lumsden,* Joanna M. Roberts, Nicola L. Harris,* Robert J. Peach,† and
Franca Ronchese2*
The CD28 costimulatory pathway is critical to T cell activation. Blockade of the interaction of CD28 with its ligands CD80 and
CD86 using CTLA4-Ig has been proposed as a therapy for a number of immune-based disorders. We have used a murine model
of influenza virus infection to study the role of CD28-dependent costimulation in the development of antiviral immune responses.
In vivo treatment with CTLA4-Ig to block the interaction of CD28 with CD80 and CD86 reduced virus-specific cytotoxicity and
IFN-g production by bronchoalveolar lavage fluid CD81 T lymphocytes in vitro. It also resulted in decreased numbers of virus-
specific CD81 T lymphocytes in the bronchoalveolar lavage fluid, lung, and spleen and lowered virus-specific Ab titers. Mice
treated with CTLA4-Ig were able to control and clear the virus infection, but this was delayed compared with controls. Treatment
with Y100F-Ig, a mutant form of CTLA4-Ig which selectively binds to CD80 and blocks the CD28-CD80 interaction leaving
CD28-CD86 binding intact, did not affect Ab production, spleen cytotoxic precursors, or clearance of virus. However, Y100F-Ig
treatment had a clear effect on lung effector cell function. Secretion of IFN-g by bronchoalveolar lavage fluid CD81 T lymphocytes
in vitro was decreased, and the number of virus-specific CD81 T lymphocytes in the bronchoalveolar lavage fluid and lungs of
infected mice was reduced. These results indicate that CD28-dependent costimulation is important in the antiviral immune
response to an influenza virus infection. The individual CD28 ligand, CD80, is important for some lung immune responses and
cannot always be compensated for by CD86. The Journal of Immunology, 2000, 164: 79–85.
T cells require two signals to proliferate and differentiateinto effector cells. One signal is Ag specific and generatedby the interaction of the TCR with antigenic peptide
bound to MHC molecules on APC. The second, or costimulatory,
signal is principally generated through engagement of the CD28
receptor on T cells with its ligands CD80 and CD86 on APC (re-
viewed in Ref. 1). It is unclear why two costimulatory ligands exist
and whether they mediate distinct roles during immune responses.
CTLA4-Ig is a soluble chimeric protein consisting of the extra-
cellular domain of CTLA-4 fused to the Fc portion of human IgG1.
This molecule has been shown in a number of models to be pow-
erfully immunosuppressive, through its ability to block CD28 in-
teraction with CD80 and CD86. CTLA4-Ig has been shown to
prevent organ transplant rejection (2, 3), lupus-like autoimmune
disease (4), experimental autoimmune encephalomyelitis (5, 6),
autoimmune oophoritis (7), and asthmatic lung inflammation (8) in
experimental models. In addition, CTLA4-Ig has been proposed as
a therapeutic agent for a number of immune-based disorders, and
phase I clinical trials in patients with psoriasis vulgaris have re-
cently been completed (9). If CTLA4-Ig is to be used in a clinical
situation, its effect on clearance of infectious agents must be es-
tablished. We have examined the antiviral immune response in a
murine model of influenza infection during concurrent treatment
with CTLA4-Ig.
Y100F-Ig is a mutant form of CTLA4-Ig that selectively binds
CD80 and blocks CD28-CD80 interactions but leaves CD28-CD86
binding intact (10). We have previously shown in a model of Ag-
induced airway eosinophilia that Y100F-Ig prevents the accumu-
lation of eosinophils and lymphocytes in the lungs of immunized
mice, but does not block Ag-induced systemic blood eosinophilia
or IgE Ab production (10). These results suggested that CD80-
dependent costimulation may be especially important for the de-
velopment of immune responses in the lung. Further in vitro evi-
dence also suggests that CD80 may be critical for the activation of
T lymphocytes in the lung. The T cell stimulatory capacity of
murine lung dendritic cells in vitro is reported to be almost exclu-
sively dependent on expression of CD80 while CD86, although
expressed, has a secondary role (11). To determine whether block-
ade of CD80-dependent costimulation can also inhibit other lung
immune responses, we investigated the effect of Y100F-Ig treat-
ment during an influenza virus infection.
Materials and Methods
Mice
C57BL/6J mice were bred and maintained at the Biomedical Research Unit
of the Wellington School of Medicine. All animal experimental procedures
used in this study were approved by the Wellington School of Medicine
Animal Ethics Committee and conducted in accordance with the guidelines
of the University of Otago (Dunedin, New Zealand).
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Reagents
Chimeric proteins derived from the fusion of the extracellular portion of
human or murine CTLA-4 to human IgG1 were used in these studies (12).
Y100F-Ig is a mutant CTLA4-Ig in which the tyrosine at position 100 is
substituted with phenylalanine (10). CTLA4-Ig and Y100F-Ig bind CD80
with indistinguishable kinetics, whereas binding of Y100F-Ig to CD86 is
undetectable (10). The mAb L6-Ig, which has a human Fc region, was used
as a control (12). Mice were injected i.p. with 200 mg of murine CTLA4-Ig,
Y100F-Ig, or L6-Ig or 400 mg of human CTLA4-Ig, Y100F-Ig, or L6-Ig,
beginning the day before infection, and continuing every 48 h throughout
the experiment.
The H-2Db-binding influenza A peptide NP366-374 (ASNENMETM;
see Ref. 13) was synthesized by Chiron Technologies (Victoria, Australia).
Virus
The A/HKx31 (H3N2) influenza A virus is a laboratory-generated recom-
binant with the external surface components of A/Aichi/2/68 (H3N2) and
the internal components of A/PR8/8/34 (H1N1) (14). Virus stocks were
grown in the allantoic cavities of 10-day-old embryonated chicken eggs
and stored as infectious allantoic fluid at 280°C. Virus stock was shown to
be endotoxin free by the Limulus amebocyte lysate assay (Sigma, St. Louis,
MO). Virus titer was determined by agglutination of human erythrocytes
and is expressed as hemagglutinating units (HAU).3 Mice were anesthe-
tized by an i.p. injection of a mixture of ketamine and xylazine (Phoenix,
Auckland, New Zealand), and 12 HAU of virus in a 30-ml volume of PBS
was administered by intranasal inoculation.
Tissue sampling
Mice were anesthetized and exsanguinated from the vena cava. The trachea
was cannulated and a bronchoalveolar lavage (BAL) performed with three
consecutive washings with 0.8 ml of PBS, each of which was infused and
withdrawn five times. BAL cells from individual mice were pooled, eryth-
rocytes were lysed in 0.14 M NH4Cl and 17 mM Tris-HCl, and nucleated
cells were adhered on plastic for 2 h at 37°C to remove macrophages.
Lungs were perfused via the heart right ventricle with 10 ml of PBS, and
minced lung tissue was digested with 2.4 mg/ml collagenase (Life Tech-
nologies, Auckland, New Zealand) and 0.1% DNase I (Sigma) for 1 h at 37°C.
Lung-infiltrating lymphocytes were purified over a 65% Percoll gradient and
the interphase cells were collected. Single-cell suspensions were prepared from
spleen by teasing though nylon gauze, and erythrocytes were lysed.
Virus titers in lung tissue
Lungs were removed at various intervals after infection and stored at
280°C until further assay. Individual lung samples were homogenized in
1 ml of IMDM (Life Technologies). Homogenates were diluted serially
10-fold in IMDM supplemented with 2 mg/ml trypsin and plated in tripli-
cate onto Madin-Darby canine kidney cells (15). The cultures were incu-
bated for 7 days at 35°C. The culture supernatants were tested for the pres-
ence of viral hemagglutinin activity by mixing 50 ml of supernatant with 50 ml
of a 0.4% suspension of human erythrocytes. Virus titers were determined by
interpolation of the last dilutions that showed hemagglutination.
Cytotoxicity assay
The cytotoxic activity of BAL and spleen cells was determined using the
just another method (JAM) test (16) on 5000 labeled EL4 cells that had
been incubated in the presence or absence of 10 mg/ml NP366-374 peptide
for 1 h at 37°C before the assay as described (17). The percentage of
cytotoxicity was calculated from the mean of triplicate wells. BAL cells
were tested directly ex vivo for cytotoxic activity. Spleen cells were first
stimulated in vitro with 0.1 mM NP366-374 peptide for 5 days. All cultures
were in IMDM containing 2 mM glutamine, 1% penicillin-streptomycin,
5 3 1025 M 2-ME (Sigma), and 5% FCS (Life Technologies).
FACS Analysis
Anti-FcgRII (2.4G2), anti-CD8 (2.43), and anti-CD4 (GK1.5) Ab were
affinity purified from tissue culture supernatants using protein G-Sepharose
(Pharmacia Biotech, Uppsala, Sweden) and conjugated with biotin. Anti-
Vb8.3-FITC was obtained from PharMingen (San Diego, CA). Cells were
stained in PBS containing 2% FCS and 0.01% sodium azide as described
(10) and analyzed on a FACSort (Becton Dickinson, Mountain View, CA).
Enzyme-Linked Immunospot
Polyvinyl chloride 96-well plates (Nunc, Roskilde, Denmark) were coated
overnight at 4°C with 20 mg/ml AN18 (anti-IFN-g) and blocked with 10%
BSA in PBS for 60 min at room temperature. After washing, freshly ex-
planted cells were added in serial dilutions. Cells were incubated with or
without 10 mg/ml of the peptide NP366-374 for 6 h at 37°C in a 5% CO2
incubator. After removal of cells, an appropriate dilution of the secondary
Ab XMG-D6-biotin was added and incubated at 4°C overnight. Alkaline
phosphatase-avidin conjugate was added and incubated for 1 h at 37°C;
spots representing single IFN-g-producing cells were revealed using the
substrate 5-bromo-4-chloro-3-indolyl phosphate (Sigma) and counted un-
der an inverted microscope.
Ab ELISA
Polyvinyl chloride 96-well plates (Nunc) were coated overnight at 4°C
with 10 mg/ml purified Influenza x31 Ag (SPAFAS, Storrs, CT), and
ELISA reactions were conducted as described previously (8). Ab titers are
expressed in U/ml (reciprocal of 50% Ab titer).
Results
Effect of CTLA4-Ig and Y100F-Ig treatment on CD81 T cell
effector function
To determine the importance of CD28-dependent costimulation
during an influenza virus infection, mice were treated with i.p.
injections of CTLA4-Ig, or the isotype control L6-Ig, every 48 h
beginning the day before infection. To assess the role of the indi-
vidual CD28 ligand CD80, mice were treated with a mutant form
of CTLA4-Ig, Y100F-Ig, which does not bind to CD86 (10). Nei-
ther Y100F-Ig nor CTLA4-Ig affected the total number of CD81 T
lymphocytes detected in the BAL of mice infected with influenza
virus at day 9 after infection. In contrast, treatment with CTLA4-
Ig, but not Y100F-Ig, considerably reduced the number of CD41
T lymphocytes in the BAL as compared with the L6-Ig treated
group (data not shown). A JAM test using EL4 cells coated with
the immunodominant peptide NP366-374 was used to detect virus-
specific CTL. BAL cells from mice treated with CTLA4-Ig exhib-
ited no cytotoxic activity (Fig. 1). No cytotoxic activity was de-
tected from BAL cells taken at day 12 after infection (data not
shown), indicating that lack of cytotoxicity was not due to a delay
in the kinetics of the appearance of CTLs in mice treated with
CTLA4-Ig. The effect of Y100F-Ig on the cytotoxic activity of
BAL lymphocytes was variable. In some experiments, the cyto-
toxic activity, although slightly diminished, was comparable to
that of controls (Fig. 1), whereas in other experiments, it was par-
tially reduced (data not shown).
To distinguish between an effect of CTLA4-Ig on CD81 T cell
priming, as opposed to an effect on the acquisition of cytotoxic
effector function in vivo, spleen cells from infected mice were
restimulated in vitro in the presence of specific peptide to allow the
differentiation of CTL precursors into effector cells before assay in
a JAM test. Cultures of spleen cells from mice treated with
Y100F-Ig showed equivalent killing to cultures from L6-Ig con-
trols (Fig. 2). In contrast, very little killing activity was detected
from spleen cell cultures from mice treated with CTLA4-Ig (Fig. 2).
This suggests that CTLA4-Ig causes a severe defect in the priming
and/or expansion of virus specific CD81 T cells during influenza
virus infection.
As an independent assay of CD81 T lymphocyte function,
enzyme-linked immunospot assays were used to evaluate the num-
ber of Ag-specific IFN-g-secreting cells. BAL lymphocytes were
collected at day 9 after infection, restimulated in culture in the
presence or absence of NP366-374 peptide for 6 h, and the number
of IFN-g-secreting cells counted. High numbers of IFN-g-produc-
ing cells could be demonstrated in the BAL of control L6-Ig-
treated mice, but only in the presence of NP366-374 peptide, indi-
cating that cytokine production was Ag specific (Fig. 3). Very few
3 Abbreviations used in this paper: HAU, hemagglutinating units; BAL, bronchoal-
veolar lavage; JAM, just another method.
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lymphocytes were found in the BAL of noninfected mice, and no
IFN-g-secreting cells were detected in lung-infiltrating lympho-
cytes isolated from noninfected mice (data not shown). The num-
ber of cytokine-secreting cells was severely reduced in mice
treated with CTLA4-Ig although some effector function was de-
tected (Fig. 3). This is in contrast to the cytotoxic assay where no
CTL activity was apparent after CTLA4-Ig treatment. In two sep-
arate experiments, Y100F-Ig reduced the number of IFN-g-secret-
ing cells in the BAL compared with controls (Fig. 3), indicating
that CD80-dependent costimulation was required for the optimal
development of IFN-g-secreting cells. The numbers of IFN-g-se-
creting CD81 T cells specific for NP366-374 in lymph node and
spleen were too low to allow a meaningful comparison.
Effect of CTLA4-Ig and Y100F-Ig on the proportion of Vb8.3
TCR1 lung lymphocytes
Because only a small percentage of lymphocytes in the BAL are
Ag specific (18), it is possible that CTLA4-Ig and Y100F-Ig are
FIGURE 1. Treatment with CTLA4-Ig abrogates the cytotoxic activity of BAL lymphocytes, whereas Y100F-Ig has marginal effects. C57BL/6J mice
(five per group) were infected intranasally with 12 HAU of influenza virus. Mice were treated i.p with either CTLA4-Ig, Y100F-Ig, or L6-Ig every 48 h
beginning the day before infection. BAL cells were collected on day 9 after infection, pooled, and depleted of macrophages by plastic adherence. Cytotoxic
activity was measured using a JAM test. The filled symbols represent killing of EL4 target cells coated with NP366-374, and the open symbols represent
killing of EL4 targets without peptide.
FIGURE 2. Treatment with CTLA4-Ig markedly reduces the cytotoxicity of in vitro stimulated splenocytes, whereas Y100F-Ig has no effect. Mice (four
per group) were treated with CTLA4-Ig, Y100F-Ig, or L6-Ig and infected with influenza virus as detailed in the legend to Fig. 1. Splenocytes were obtained from
groups of mice 9 days after infection and restimulated in vitro with 0.1 mM NP366-374. After 5 days of culture, cells were tested for cytotoxic activity by a JAM
test. The filled symbols represent killing of EL4 target cells coated with NP366-374, and the open symbols represent killing of EL4 targets without peptide.
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inhibiting either the infiltration of Ag-specific cells into the lung or
the further activation of cells to effector function once they are in
the lung. Therefore, we sought to determine the proportion of
Ag-specific cells in the BAL. Cells taken directly from the BAL of
infected mice exhibit a preferential accumulation of Vb8.31CD81
T cells (19), as the Vb8.3 TCR is selectively overrepresented in
the CD81, NP366-374-specific population. As an estimate of the
proportion of Ag-specific cells, we measured the expression of
Vb8.3 on BAL lymphocytes by FACS analysis. As expected, the
usage of the Vb8.3 TCR on CD41 cells was equivalent in all
treatment groups and did not change over the time course of the
infection (Fig. 4). In contrast, the proportion of Vb8.3-expressing
cells in the CD81 population was significantly increased in the
L6-Ig-treated group compared with noninfected mice. The propor-
tion of Vb8.3 cells was increased at day 9 and further expanded at
day 13 (Fig. 4), presumably as a result of more rapid clearance of
non-virus-specific cells from the lung. Infected mice treated with
CTLA4-Ig had marginal or no increase in the proportion of
Vb8.31CD81 cells in both the lung and BAL. This suggests that
very few NP366-374-specific CD81 T cells are present in the lung
and BAL fluid of CTLA4-Ig-treated mice. Finally, an increase in
the proportion of Vb8.31CD81 cells was detected in both the lung
and BAL fluid of Y100F-Ig-treated mice (Fig. 4). This increase
was usually, but not always, less profound than the increase ob-
served in control L6-Ig-treated mice (data not shown), suggesting
that lower numbers of Ag-specific cells were present in the lung
and BAL fluid of Y100F-Ig-treated mice.
Effect of CTLA4-Ig and Y100F-Ig on Ab production
To determine the requirement of CD28-dependent costimulation
for Ab production, virus-specific IgG1 and IgG2a titers were mea-
sured in CTLA4-Ig, Y100F-Ig, and L6-Ig-treated mice using an
FIGURE 3. Treatment with CTLA4-Ig or Y100F-Ig reduces the number
of Ag-specific IFN-g-secreting cells in the BAL. Mice (three per group)
were treated with CTLA4-Ig, Y100F-Ig, or L6-Ig and infected with influ-
enza virus as detailed in the legend to Fig. 1. Freshly isolated BAL cells
were collected on day 9 after infection, pooled, and depleted of macro-
phages by plastic adherence. The filled bars represent the number of IFN-
g-secreting cells/106 cells after a 6-h restimulation with NP366-374. The
open bars represent the number of IFN-g-secreting cells/106 cells after a
6-h incubation without peptide.
FIGURE 4. Treatment with CTLA4-Ig or Y100F-Ig reduces the accumulation of Vb8.31CD81 cells in the BAL and lung. Mice (three per group) were
treated with CTLA4-Ig, Y100F-Ig, or L6-Ig and infected with influenza virus as detailed in the legend to Fig. 1. Freshly isolated BAL cells and
lung-infiltrating lymphocytes were collected at the indicated time points after infection, pooled, and depleted of macrophages by plastic adherence. The
percentages of CD41 cells (open bars) and CD81 cells (filled bars) which were Vb8.31 were determined by FACS analysis.
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ELISA. Results showed that both IgG1 and IgG2a were lowered
by CTLA4-Ig treatment (Fig. 5). The mean titer of IgG1 was 30-
fold lower than in the L6-Ig controls, and the mean titer of IgG2a
was 7-fold lower. Levels of IgG1 and IgG2a were similar in
Y100F-Ig- and L6-Ig-treated mice (Fig. 5). Serum from nonin-
fected mice had undetectable levels of both IgG1 and IgG2a (data
not shown). Mice depleted of CD41 T cells (20) and mice deficient
in expression of MHC class II molecules (J. M. Lumsden and F.
Ronchese, unpublished data) are still able to produce influenza-
specific Abs, especially IgG2a, albeit at a reduced level. This sug-
gests that a component of the Ab response to influenza virus in-
fection is CD41 T cell independent, which may explain why
reasonable titers of Ab were detected even when CD28-dependent
costimulation was blocked.
Effect of CTLA4-Ig and Y100F-Ig treatment on virus clearance
Influenza virus clearance is mediated by CD81 cytotoxic T cells,
but other mechanisms such as Ab can clear the infection when
CD81 cells are absent (21, 22). To determine whether the defects
in T cell activity observed in mice treated with CTLA4-Ig or
Y100F-Ig influenced virus clearance, infectious virus titers were
measured at days 6 and 9 after infection. As shown in Fig. 6,
Y100F-Ig did not alter the rate of clearance of virus from infected
lungs. In contrast, mice treated with CTLA4-Ig showed delayed
virus clearance. In other experiments, we found that all mice
treated with CTLA4-Ig had cleared the virus by day 12, indicating
that virus clearance is ultimately achieved in CTLA4-Ig-treated
mice (data not shown).
Discussion
The aim of the present study was to establish whether blockade of
CD80/CD86-dependent costimulation affects the development of
an anti-influenza immune response, and more specifically, to es-
tablish the relative importance of the CD80 costimulatory mole-
cule in the lung immune response. Our experiments revealed that
both CTLA4-Ig and Y100F-Ig had significant effects on the anti-
influenza virus immune response.
CTLA4-Ig-treated mice had decreased Ab production, no de-
tectable ex vivo cytotoxic activity, and reduced Ag-specific secre-
tion of IFN-g by BAL lymphocytes. The defect in CD81 T cell
function was likely to be due to lack of priming and/or expansion
of virus specific CD81 T cells, since the proportion of CD81 T
cells expressing a Vb8.3 TCR, which is preferentially expressed
on NP366-374-specific CD81 T cells, was not increased. In addi-
tion, no cytotoxic activity was detected even after lymphocyte cul-
ture in vitro in the presence of specific peptide, to allow the acti-
vation of CTLp to effector cells. We think these effects are due to
a direct effect of CTLA4-Ig on CD81 T cell activation, rather than
to an indirect effect through inhibition of CD41 T cell help. Mice
that are deficient in CD41 T cells have an equivalent level of CTL
activity in the BAL compared with wild-type mice and are able to
eliminate influenza virus from the lung with near to normal kinet-
ics (Refs. 23 and 24 and J. M. Lumsden and F. Ronchese, unpub-
lished results).
Immune responses to viral infectious agents are variously af-
fected by the blockade of the CD28 costimulatory pathway.
CD282/2 mice (25) and mice transgenic for a soluble form
of CTLA4-Ig (26) infected with lymphocytic choriomeningitis
virus generated a normal CTL response. In contrast, infection with
vesicular stomatitis virus did not induce any measurable CTL ac-
tivity. It was suggested that the requirement for CD28 costimula-
tion correlates inversely with viral replication and that high Ag
FIGURE 5. Treatment with CTLA4-Ig re-
duces the titer of virus-specific IgG1 and
IgG2a, whereas Y100F-Ig has no effect. Mice
were treated with CTLA4-Ig, Y100F-Ig, or
L6-Ig and infected with influenza virus as de-
tailed in the legend to Fig. 1. Serum was col-
lected at day 12 after infection, and virus-
specific Ab levels were determined by
ELISA. Symbols represent serum Ab titers
from individual mice; the horizontal line rep-
resents the geometric mean for each group.
FIGURE 6. Treatment with CTLA4-Ig delays the clearance of virus
from infected lungs, whereas Y100F-Ig has no effect. Groups of mice were
treated with CTLA4-Ig, Y100F-Ig, or L6-Ig and infected with influenza
virus as detailed in the legend to Fig. 1. Titers of infectious HKx31 virus
in lung extracts, obtained from individual mice at the indicated time points
after infection, were determined in the Madin-Darby kidney cell assay.
Symbols represent virus titers from individual mice.
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expression driven by these infectious agents may decrease the de-
pendency on the CD28 costimulatory signal, essentially by in-
creasing the strength of the Ag-specific “signal one.” Influenza
virus causes a transient infection of epithelial cells in the respira-
tory tract, but causes no productive infection of cells in other tis-
sues. This localized infection would be likely to produce a lower
level of Ag than viruses such as lymphocytic choriomeningitis
virus and may explain why CTLA4-Ig can inhibit the immune
response during an influenza infection. However, some T cell ac-
tivation must have occurred in mice treated with CTLA4-Ig. Mice
lacking T cells cannot control an influenza virus infection (27, 28),
whereas mice treated with CTLA4-Ig were able to control and
clear the virus, although with delayed kinetics. The observed low
level of IFN-g production by BAL cells also supports a limited
degree of T cell activation in CTLA4-Ig-treated mice.
In previous studies, we have reported that CD80 is essential to
the development of allergic lung inflammation in a murine model
(10). Treatment with Y100F-Ig drastically inhibited the develop-
ment of Ag-dependent airway eosinophilia, but had no effect on
blood eosinophilia or Ab production, indicating a preferential ef-
fect on lung immune responses. A similar role for CD80 is also
suggested by the observations reported in this study. The cytotoxic
activity of BAL CD81 lymphocytes was reduced, sometimes only
marginally (Fig. 1), sometimes more significantly (data not
shown). The number of IFN-g-secreting cells in the BAL was also
reduced, although not as severely as in CTLA4-Ig-treated mice.
Finally, the proportion of Vb8.31CD81 cells in the lung and BAL
of infected mice treated with Y100F-Ig was generally, but not
always, reduced compared with that of controls. In contrast to this
partial but still clear effect on lung immune responses, Y100F-Ig
had no effect on systemic antiviral immune responses, as measured
by spleen cytotoxic activity and Ab titers. These data suggest that
the function of CD80 in lung immune responses is not as easily
compensated for by CD86, as it is in the case of systemic immune
responses. The mechanism for this effect of Y100F-Ig is still un-
clear, but one mechanism may be to inhibit the proliferation of
Ag-specific cells in the draining lymph nodes. More accurate es-
timation of the numbers of Ag-specific cells using tetrameric MHC
class I reagents may elucidate this. It is also possible that the re-
duced cytotoxicity and IFN-g production by BAL CD81 cells was
caused by a defect in the acquisition of effector function once in
the lung. The primary APC presenting viral Ags in the lung is
likely to be the dendritic cell. Masten et al. (11) reported that the
T cell stimulatory capacity of murine lung dendritic cells in vitro
is almost exclusively dependent on expression of CD80, whereas
CD86, although expressed, has a secondary role. This may provide
another hypothesis as to the mechanism by which Y100F-Ig affects
lung effector function. It would also be interesting to see whether
increased expression of CD86 on lung APCs would overcome the
requirement for CD80 for complete lung effector cell activity.
Treatment with CTLA4-Ig and Y100F-Ig appeared to affect dif-
ferentially CD81 T cell functions such as cytotoxicity and IFN-g
production. CTL activity was completely inhibited by CTLA4-Ig
treatment. In contrast, IFN-g production was still demonstrable
although at a much reduced level. The lack of cytotoxic activity by
CD81 cells may reflect a lower sensitivity of this assay or may
indicate a higher dependence of cytotoxic function on costimula-
tory signals. Other cases of differential costimulatory requirements
for different T cell functions have been reported in the literature.
The absence of costimulation during the in vitro activation of a
CD81 T cell clone had differential effects on certain TCR-depen-
dent effector functions (29). In that study, cytotoxic activity was
not affected while IFN-g production was reduced. Recently, trans-
genic CD81 T cells rendered anergic in vivo were shown to pro-
duce IFN-g in vivo but were unable to proliferate or to kill target
cells in vitro (30, 31). The difference in the activation status of the
T cells examined in the above studies (T cell clones vs naive T
cells) may explain the discrepancies in the observed effects. It is
interesting that, in our study, Y100F-Ig had an inverse effect on
CD81 T cell function as compared with CTLA4-Ig. CTLA4-Ig
completely blocked cytotoxic activity but left some IFN-g produc-
tion. Y100F-Ig had a consistent effect on IFN-g production, but
affected cytotoxicity less extensively and less reproducibly. Again,
this suggests that although CD86 may provide sufficient costimu-
lation for some T cell functions, CD80 serves a specific function
and is required for some T cell activities. Since CD80 is reported
to be up-regulated slowly by APC (32, 33), its predominant role
may be in late T cell effector functions. Indeed, a recent paper (34)
described how acquisition of CTL activity by CD81 cells requires
only one cell division, while IFN-g production is a late event (35).
In conclusion, we show that CD28-dependent costimulation is
critical to the development of an effective anti-influenza virus im-
mune response. We also present evidence in favor of an important
role of CD80 in lung immune responses, confirming the hypothesis
that CD80 and CD86 molecules have differential roles in the de-
velopment of immune responses.
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